Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth

doi:10.1038/s41388-023-02604-x

. 2023 Mar;42(12):926-937.

doi: 10.1038/s41388-023-02604-x. Epub 2023 Feb 1.

Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth

Emma Scott¹, Kirsty Hodgson¹, Beatriz Calle^{2

3}, Helen Turner⁴, Kathleen Cheung¹, Abel Bermudez⁵, Fernando Jose Garcia Marques⁵, Hayley Pye⁶, Edward Christopher Yo¹, Khirul Islam⁷, Htoo Zarni Oo^{8

9}, Urszula L McClurg¹⁰, Laura Wilson¹¹, Huw Thomas¹¹, Fiona M Frame¹², Margarita Orozco-Moreno¹, Kayla Bastian¹, Hector M Arredondo¹³, Chloe Roustan¹⁴, Melissa Anne Gray¹⁵, Lois Kelly¹, Aaron Tolson¹, Ellie Mellor¹, Gerald Hysenaj¹, Emily Archer Goode¹, Rebecca Garnham¹, Adam Duxfield¹, Susan Heavey⁶, Urszula Stopka-Farooqui⁶, Aiman Haider¹⁶, Alex Freeman¹⁶, Saurabh Singh¹⁷, Edward W Johnston¹⁷, Shonit Punwani¹⁷, Bridget Knight¹⁸, Paul McCullagh¹⁹, John McGrath²⁰, Malcolm Crundwell²⁰, Lorna Harries²¹, Denisa Bogdan²², Daniel Westaby^{22

23}, Gemma Fowler²², Penny Flohr²², Wei Yuan²², Adam Sharp^{22

23}, Johann de Bono^{22

23}, Norman J Maitland¹², Simon Wisnovsky²⁴, Carolyn R Bertozzi²⁵, Rakesh Heer^{11

26}, Ramon Hurtado Guerrero^{27

28}, Mads Daugaard^{8

9}, Janne Leivo^{7

29}, Hayley Whitaker⁶, Sharon Pitteri⁵, Ning Wang¹³, David J Elliott¹, Benjamin Schumann^{2

3}, Jennifer Munkley³⁰

Affiliations

¹ Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, NE1 3BZ, UK.
² The Chemical Glycobiology Laboratory, The Francis Crick Institute, NW1 1AT, London, UK.
³ Department of Chemistry, Imperial College London, W12 0BZ, London, UK.
⁴ Cellular Pathology, The Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, UK.
⁵ Canary Center at Stanford for Cancer Early Detection, Department of Radiology, Stanford University, Palo Alto, CA, 94304, USA.
⁶ Molecular Diagnostics and Therapeutics Group, Charles Bell House, Division of Surgery and Interventional Science, University College London, London, UK.
⁷ Department of Life Technologies, Division of Biotechnology, University of Turku, Turku, Finland.
⁸ Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada.
⁹ Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada.
¹⁰ Institute for Integrative Biology, University of Liverpool, Liverpool, L69 7ZB, UK.
¹¹ Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Paul O'Gorman Building, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.
¹² Cancer Research Unit, Department of Biology, University of York, Heslington, North Yorkshire, YO10 5DD, UK.
¹³ The Mellanby Centre for Musculoskeletal Research, Department of Oncology and Metabolism, The University of Sheffield, Sheffield, UK.
¹⁴ Structural Biology Science Technology Platform, The Francis Crick Institute, NW1 1AT, London, UK.
¹⁵ Sarafan Chem-H and Departemnt of Chemistry, Stanford University, 424 Santa Teresa St, Stanford, CA, 94305, USA.
¹⁶ Department of Pathology, UCLH NHS Foundation Trust, London, UK.
¹⁷ UCL Centre for Medical Imaging, Charles Bell House, University College London, London, UK.
¹⁸ NIHR Exeter Clinical Research Facility, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
¹⁹ Department of Pathology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
²⁰ Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
²¹ Institute of Biomedical and Clinical Sciences, Medical School, College of Medicine and Health, University of Exeter, Exeter, UK.
²² Division of Clinical Studies, The Institute of Cancer Research, London, SM2 5NG, UK.
²³ Prostate Cancer Targeted Therapy Group, The Royal Marsden Hospital, London, SM2 5PT, UK.
²⁴ University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, V6T 1Z3, Canada.
²⁵ Howard Hughes Medical Institute, 424 Santa Teresa St, Stanford, CA, 94305, USA.
²⁶ Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE7 7DN, UK.
²⁷ University of Zaragoza, Mariano Esquillor s/n, Campus Rio Ebro, Edificio I+D, Zaragoza, Spain; Fundación ARAID, 50018, Zaragoza, Spain.
²⁸ Copenhagen Center for Glycomics, Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.
²⁹ InFLAMES Research Flagship Center, University of Turku, Turku, Finland.
³⁰ Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, NE1 3BZ, UK. Jennifer.munkley@ncl.ac.uk.

PMID: 36725887
PMCID: PMC10020086
DOI: 10.1038/s41388-023-02604-x

Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth

Emma Scott et al. Oncogene. 2023 Mar.

. 2023 Mar;42(12):926-937.

doi: 10.1038/s41388-023-02604-x. Epub 2023 Feb 1.

Authors

Affiliations

¹ Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, NE1 3BZ, UK.
² The Chemical Glycobiology Laboratory, The Francis Crick Institute, NW1 1AT, London, UK.
³ Department of Chemistry, Imperial College London, W12 0BZ, London, UK.
⁴ Cellular Pathology, The Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, UK.
⁵ Canary Center at Stanford for Cancer Early Detection, Department of Radiology, Stanford University, Palo Alto, CA, 94304, USA.
⁶ Molecular Diagnostics and Therapeutics Group, Charles Bell House, Division of Surgery and Interventional Science, University College London, London, UK.
⁷ Department of Life Technologies, Division of Biotechnology, University of Turku, Turku, Finland.
⁸ Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada.
⁹ Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada.
¹⁰ Institute for Integrative Biology, University of Liverpool, Liverpool, L69 7ZB, UK.
¹¹ Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Paul O'Gorman Building, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.
¹² Cancer Research Unit, Department of Biology, University of York, Heslington, North Yorkshire, YO10 5DD, UK.
¹³ The Mellanby Centre for Musculoskeletal Research, Department of Oncology and Metabolism, The University of Sheffield, Sheffield, UK.
¹⁴ Structural Biology Science Technology Platform, The Francis Crick Institute, NW1 1AT, London, UK.
¹⁵ Sarafan Chem-H and Departemnt of Chemistry, Stanford University, 424 Santa Teresa St, Stanford, CA, 94305, USA.
¹⁶ Department of Pathology, UCLH NHS Foundation Trust, London, UK.
¹⁷ UCL Centre for Medical Imaging, Charles Bell House, University College London, London, UK.
¹⁸ NIHR Exeter Clinical Research Facility, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
¹⁹ Department of Pathology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
²⁰ Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
²¹ Institute of Biomedical and Clinical Sciences, Medical School, College of Medicine and Health, University of Exeter, Exeter, UK.
²² Division of Clinical Studies, The Institute of Cancer Research, London, SM2 5NG, UK.
²³ Prostate Cancer Targeted Therapy Group, The Royal Marsden Hospital, London, SM2 5PT, UK.
²⁴ University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, V6T 1Z3, Canada.
²⁵ Howard Hughes Medical Institute, 424 Santa Teresa St, Stanford, CA, 94305, USA.
²⁶ Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE7 7DN, UK.
²⁷ University of Zaragoza, Mariano Esquillor s/n, Campus Rio Ebro, Edificio I+D, Zaragoza, Spain; Fundación ARAID, 50018, Zaragoza, Spain.
²⁸ Copenhagen Center for Glycomics, Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.
²⁹ InFLAMES Research Flagship Center, University of Turku, Turku, Finland.
³⁰ Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, NE1 3BZ, UK. Jennifer.munkley@ncl.ac.uk.

PMID: 36725887
PMCID: PMC10020086
DOI: 10.1038/s41388-023-02604-x

Abstract

Prostate cancer is the most common cancer in men and it is estimated that over 350,000 men worldwide die of prostate cancer every year. There remains an unmet clinical need to improve how clinically significant prostate cancer is diagnosed and develop new treatments for advanced disease. Aberrant glycosylation is a hallmark of cancer implicated in tumour growth, metastasis, and immune evasion. One of the key drivers of aberrant glycosylation is the dysregulated expression of glycosylation enzymes within the cancer cell. Here, we demonstrate using multiple independent clinical cohorts that the glycosyltransferase enzyme GALNT7 is upregulated in prostate cancer tissue. We show GALNT7 can identify men with prostate cancer, using urine and blood samples, with improved diagnostic accuracy than serum PSA alone. We also show that GALNT7 levels remain high in progression to castrate-resistant disease, and using in vitro and in vivo models, reveal that GALNT7 promotes prostate tumour growth. Mechanistically, GALNT7 can modify O-glycosylation in prostate cancer cells and correlates with cell cycle and immune signalling pathways. Our study provides a new biomarker to aid the diagnosis of clinically significant disease and cements GALNT7-mediated O-glycosylation as an important driver of prostate cancer progression.

PubMed Disclaimer

Conflict of interest statement

JM is shareholder and Scientific Advisor of GlycoScoreDx Ltd. ES and GH are shareholders of GlycoScoreDx Ltd. The authors have filed a patent relating to this work (GB Patent GB2,594,103). CRB is a cofounder and scientific advisory board member of Lycia Therapeutics, Palleon Pharmaceuticals, EnableBioscience, Redwood Biosciences (a subsidiary of Catalent), OliLux Bio, Grace Science LLC, and InterVenn Biosciences. The other authors declare no competing interests.

Figures

**Fig. 1. GALNT7 is upregulated in prostate cancer tissue.**
Analysis of GALNT7 gene and protein levels in clinical prostate tissue. A *GALNT7* mRNA levels in the TCGA PRAD cohort [24] are significantly higher in prostate cancer tissue relative to normal prostate tissue (n = 549, unpaired t test, p = <0.001). B Real-time PCR analysis of *GALNT7* in RNA samples extracted from FFPE prostate tissue. *GALNT7* is significantly upregulated in cancer relative to benign tissue (n = 12, unpaired t test, p = 0.0174). C Real-time PCR analysis of GALNT7 mRNA in matched normal and prostate tumour samples. *GALNT7* is upregulated in tumour tissue relative to matched normal tissue from the same patient (n = 20, paired t test, p = 0.0357). D Immunohistochemistry analysis of GALNT7 protein in a previously published prostate cancer tissue microarray (TMA) [25]. Each section was scored using the Histoscore method [77, 78]. GALNT7 is upregulated in prostate cancer tissue relative to benign prostate hyperplasia tissue (BPH) (n = 147, unpaired t test, p < 0.001). Scale bar is 100 µm. E Immunohistochemistry analysis of GALNT7 protein in a previously published TMA containing matched tumour and normal tissue from the same patient [79]. GALNT7 protein is significantly increased in prostate tumour tissue relative to matched normal tissue from the same patient (n = 200, paired t test, p < 0.001). Scale bar is 100 µm.

**Fig. 2. GALNT7 is upregulated in the urine and blood from men with prostate cancer.**
Detection of GALNT7 in patient urine and blood samples from 3 patient cohorts using pre-validated sandwich ELISA assays. **A, B** GALNT7 protein levels detected by sandwich ELISA assays in urine and matched plasma samples from men with suspected prostate cancer. Compared to men with benign disease, GALNT7 urine levels are higher in men with prostate cancer (n = 27, unpaired t test, p = 0.082) (AUC 0.78, sensitivity 87%, specificity 58%). Additionally, GALNT7 plasma levels are significantly higher in men with prostate cancer (n = 27, unpaired t test, p = 0.0172)(AUC 0.79, sensitivity 93%, specificity 42%). C GALNT7 levels are significantly higher in plasma samples from men with prostate cancer compared to men with benign disease (n = 305, unpaired t test, p < 0.0001)(AUC 0.83, sensitivity 85%, specificity 65%). D GALNT7 urine levels were monitored via sandwich ELISA assays in 180 men with suspected prostate cancer taking part in the INNOVATE clinical trial [31]. GALNT7 urine levels are significantly higher in men who were diagnosed with prostate cancer, compared to men who received a ‘no cancer’ diagnosis (n = 180, unpaired t test, p < 0.0001). GALNT7 urine level was more accurate than serum PSA at identifying men with prostate cancer (urine GALNT7 AUC: 0.73, sensitivity 85%, specificity 41%)(serum PSA AUC: sensitivity 85%, specificity 38%). E For the 180 men with suspected prostate cancer taking part in the INNOVATE clinical trial, the combination of serum PSA and urine GALNT7 had the greatest diagnostic power to identify those with prostate cancer (AUC 0.76, sensitivity 85%, specificity 58%). F For men taking part in the INNOVATE study that received mpMRI scored Likert 3, GALNT7 levels were significantly higher in men with prostate cancer (n = 59, unpaired t test, p = 0.0001)(AUC 0.78).

**Fig. 3. GALNT7 levels remain high in castrate resistant prostate cancer.**
Analysis of GALNT7 protein levels across two prostate cancer tissue microarrays (TMAs) using immunohistochemistry and in serum samples using sandwich ELISA assays. A Immunohistrochemistry analysis of GALNT7 levels in a previously published TMA [26]. GALNT7 levels in tumour tissue are significantly reduced after neoadjuvant hormonal therapy (NHT) (n = 162, unpaired t test, p < 0.0001). Scale bar is 100 µm. B Analysis of a 125 case TMA reveals the levels of GALNT7 in hormone naïve and castrate resistant prostate cancer (CRPC) are similar. Scale bar is 100 µm. C GALNT7 serum levels significantly decrease following ADT (n = 20, Mann Whitney U test, p = 0.0039). D The serum levels of GALNT7 in men with mCRPC are significantly higher than in men with hormone naïve prostate cancer (n = 260, unpaired t test, p < 0.001). E In the SU2C mCRPC patient cohort (n = 163) [33, 80] GALNT7 mRNA levels correlate with the androgen response pathway (NES 2.45; FDR q value = <0.001).

**Fig. 4. GALNT7 can modify O-glycosylation in prostate cancer cells.**
A Lectin flow cytometry shows PC3 cells with upregulated GALNT7 have increased binding to SBA lectin (which recognises terminal GalNAc or Tn antigen). B Detection of the cancer-associated Tn antigen by immunofluorescence in DU145 cells show upregulation of GALNT7 promotes increased expression of the Tn antigen. C Analysis of extracellular vesicles (EVs) in conditioned media from LNCaP and DU145 cells with knockdown or overexpression of GALNT7 suggests a correlation between GALNT7 and the Tn antigen in the prostate cancer secretome. D Detection of glycosylation of secreted proteins in samples from PC3 control cells or GALNT7-KO cells using GALNT7 bump-and-hole engineering. The active site of GALNT7 was engineered by mutation (IIe and Leu to 2xAla). The mutant (termed BH) uses a chemically modified analogue of the native substrate UDP-GalNAc. Following glycosylation, the chemical modification can be traced by methods of click chemistry.

**Fig. 5. GALNT7 promotes prostate tumour growth and correlates with cell cycle and immune signalling pathways in prostate cancer cells.**
A Knockdown of GALNT7 using shRNA significantly reduces the growth of CWR22RV1 tumours xenografts in a subcutaneous xenograft model. B Upregulation of GALNT7 in PC3 cells significantly increases the growth of subcutaneous xenograft tumours. C Knockdown of GALNT7 decreases prostate cancer cell invasion and upregulation of GALNT7 promotes prostate cancer cell invasion. D RNAseq analysis of CWR22RV1 cells with knockdown of GALNT7 and DU145 cells with upregulated GALNT7 identified 457 genes that dynamically change in response to GALNT7. Gene Ontology analysis of the 457 genes regulated by GALNT7 shows an enrichment of genes with roles in the ‘cell cycle’ and a de-enrichment of genes with roles in ‘immune signalling’. E Proteomics analysis of DU145 cells with upregulation of GALNT7 identified 249 proteins with a significant change in expression levels. Revigo analysis of these 249 proteins identified ‘cell cycle’ and ‘immune signalling’ as significantly enriched pathways. F Analysis of the SU2C mCRPC cohort [33] identified immune related pathways (including interferon gamma response, interferon alpha response, complement, allograft rejection, IL6 signalling, TNFA Signaling via NFKB and inflammatory response) with attenuated enrichment with *GALNT7* expression.

See this image and copyright information in PMC

Comment in

The role of GALNT7 as a potential diagnostic marker in prostate cancer.
Masone MC. Masone MC. Nat Rev Urol. 2023 Apr;20(4):198. doi: 10.1038/s41585-023-00756-9. Nat Rev Urol. 2023. PMID: 36918685 No abstract available.
Temporary cessation versus continued TKI therapy for RCC.
Masone MC. Masone MC. Nat Rev Urol. 2023 Apr;20(4):198. doi: 10.1038/s41585-023-00755-w. Nat Rev Urol. 2023. PMID: 36922603 No abstract available.

Cited by

Mucin Glycans: A Target for Cancer Therapy.
Sun L, Zhang Y, Li W, Zhang J, Zhang Y. Sun L, et al. Molecules. 2023 Oct 11;28(20):7033. doi: 10.3390/molecules28207033. Molecules. 2023. PMID: 37894512 Free PMC article. Review.
Rational Design of Dual-Domain Binding Inhibitors for N-Acetylgalactosamine Transferase 2 with Improved Selectivity over the T1 and T3 Isoforms.
Compañón I, Ballard CJ, Lira-Navarrete E, Santos T, Monaco S, Muñoz-García JC, Delso I, Angulo J, Gerken TA, Schjoldager KT, Clausen H, Tejero T, Merino P, Corzana F, Hurtado-Guerrero R, Ghirardello M. Compañón I, et al. JACS Au. 2024 Sep 11;4(9):3649-3656. doi: 10.1021/jacsau.4c00633. eCollection 2024 Sep 23. JACS Au. 2024. PMID: 39328774 Free PMC article.
Sialylation Inhibition Can Partially Revert Acquired Resistance to Enzalutamide in Prostate Cancer Cells.
Goode EA, Orozco-Moreno M, Hodgson K, Nabilah A, Murali M, Peng Z, Merx J, Rossing E, Pijnenborg JFA, Boltje TJ, Wang N, Elliott DJ, Munkley J. Goode EA, et al. Cancers (Basel). 2024 Aug 24;16(17):2953. doi: 10.3390/cancers16172953. Cancers (Basel). 2024. PMID: 39272811 Free PMC article.
The role of protein post-translational modifications in prostate cancer.
Hao Y, Gu C, Luo W, Shen J, Xie F, Zhao Y, Song X, Han Z, He J. Hao Y, et al. PeerJ. 2024 Aug 12;12:e17768. doi: 10.7717/peerj.17768. eCollection 2024. PeerJ. 2024. PMID: 39148683 Free PMC article. Review.
A Bioorthogonal Precision Tool for Human N-Acetylglucosaminyltransferase V.
Liu Y, Bineva-Todd G, Meek RW, Mazo L, Piniello B, Moroz O, Burnap SA, Begum N, Ohara A, Roustan C, Tomita S, Kjaer S, Polizzi K, Struwe WB, Rovira C, Davies GJ, Schumann B. Liu Y, et al. J Am Chem Soc. 2024 Oct 2;146(39):26707-26718. doi: 10.1021/jacs.4c05955. Epub 2024 Sep 17. J Am Chem Soc. 2024. PMID: 39287665 Free PMC article.

See all "Cited by" articles

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. doi: 10.3322/caac.21332. - DOI - PubMed
1. Livermore K, Munkley J. DJ E. Androgen receptor and prostate cancer. AIMS Mol Sci. 2016;3:280–99. doi: 10.3934/molsci.2016.2.280. - DOI
1. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005. doi: 10.1056/NEJMoa1014618. - DOI - PMC - PubMed
1. Beer TM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:1755–6. doi: 10.1056/NEJMoa1405095. - DOI - PubMed
1. Morote J, Aguilar A, Planas J, Trilla E. Definition of Castrate Resistant Prostate Cancer: New Insights. Biomedicines. 2022;10:689. doi: 10.3390/biomedicines10030689. - DOI - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Molecular Biology Databases
- NIAID Data Ecosystem - Find datasets on Infectious and Immune-mediated Diseases
Research Materials
- Addgene Non-profit plasmid repository
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. doi: 10.3322/caac.21332. - DOI - PubMed

[2] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. doi: 10.3322/caac.21332. - DOI - PubMed

[3] Livermore K, Munkley J. DJ E. Androgen receptor and prostate cancer. AIMS Mol Sci. 2016;3:280–99. doi: 10.3934/molsci.2016.2.280. - DOI

[4] Livermore K, Munkley J. DJ E. Androgen receptor and prostate cancer. AIMS Mol Sci. 2016;3:280–99. doi: 10.3934/molsci.2016.2.280. - DOI

[5] de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005. doi: 10.1056/NEJMoa1014618. - DOI - PMC - PubMed

[6] de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005. doi: 10.1056/NEJMoa1014618. - DOI - PMC - PubMed

[7] Beer TM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:1755–6. doi: 10.1056/NEJMoa1405095. - DOI - PubMed

[8] Beer TM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:1755–6. doi: 10.1056/NEJMoa1405095. - DOI - PubMed

[9] Morote J, Aguilar A, Planas J, Trilla E. Definition of Castrate Resistant Prostate Cancer: New Insights. Biomedicines. 2022;10:689. doi: 10.3390/biomedicines10030689. - DOI - PMC - PubMed

[10] Morote J, Aguilar A, Planas J, Trilla E. Definition of Castrate Resistant Prostate Cancer: New Insights. Biomedicines. 2022;10:689. doi: 10.3390/biomedicines10030689. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth

Affiliations

Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Research Materials

Miscellaneous

Abstract

Conflict of interest statement

Figures

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Research Materials

Miscellaneous